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Abstract: Although several reviews on canine leishmaniasis have been
published, none thoroughly described clinicopathologic abnormalities and
their clinical usefulness. The aim of this review was to provide information
concerning current diagnostic tests relevant for clinical pathologists and
from a practical perspective. Specifically, in canine leishmaniasis, nonre-
generative normocytic normochromic anemia, thrombocytopenia, or
leukogram changes may be present. Clinical chemistry and urinalysis may
indicate renal dysfunction (azotemia, decreased urine specific gravity, pro-
teinuria) and an inflammatory/immune response (increased acute phase
proteins [APP] or a2- and/or c-globulins). Although a potential gammopa-
thy is usually polyclonal, it may also appear oligo- or monoclonal, espe-
cially in dogs coinfected by other vector-borne pathogens. When lesions
are accessible to fine-needle aspiration (lymphoadenomegaly, nodular
lesions, joint swelling), cytology is strongly advised, as the presence of
Leishmania amastigotes in a pattern of pyogranulomatous inflammation or
lymphoplasmacytic hyperplasia is diagnostic. If the cytologic pattern is
inconclusive, the parasite should be identified by histology/immunohisto-
chemistry or PCR on surgical biopsies. Alternatively, cytology and PCR
may be performed on bonemarrow samples where amastigotes, along with
erythroid hypoplasia, myeloid hyperplasia, plasmacytosis, or secondary
dysmyelopoiesis can be observed. Dogs with overt leishmaniasis generally
have high antibody titers, while low titers predominate in immunologically
resistant infected dogs or in exposed dogs with no parasite confirmation.
Quantitative serology is recommended in clinically suspect dogs as high-
titer antibodies titers may confirm the clinical diagnosis. In confirmed and
treated dogs, renal function and inflammatory/immune response variables
should be periodically monitored.
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Introduction
Leishmaniasis is a frequent infectious disease of dogs
living in endemic areas, associated with important
morbidity and, despite appropriate treatment, poten-
tial lethal outcome. Although several reviews have
been published so far, none has fully described the
diagnostic role of available laboratory tests that may be
diagnostic or of value for monitoring dogs with leish-
maniasis. Therefore, the aim of the present review was
to provide information concerning typical laboratory
abnormalities and current diagnostic tests that may be
relevant for clinical pathologists, from a practical
perspective.
Etiology and Pathogenesis of Canine
Leishmaniasis
Canine leishmaniasis is caused by the protozoan para-
site Leishmania infantum or its New World synonym
Leishmania chagasi.1 Although nonvectorial transmis-
sion has been reported (eg, transplacental, transfu-
sional, or venereal)2–4, the parasite is usually
transmitted by infected phlebotomine sand flies.
Therefore, the geographic distribution and prevalence
of the disease depend on the presence and abundance
of competent vectors.5 Blood-sucking females ingest
the nonflagellated form (amastigote) during the blood-
meal on infected hosts. After multiplication, flagellated
forms (promastigotes) transform into infectious meta-
cyclic promastigotes that are inoculated into the host
at the next blood meal. Parasites are phagocytosed by
macrophages6; however, the amastigotes are resistant
to phagolysosomal digestion due to interference with
the oxidative activity of these cells7,8 and survive and
replicate in macrophages. As a result, more and more
macrophages become progressively infected and
destroyed.
In longitudinal field studies on na€ıve dogs, Leish-
mania can be detected by PCR in bone marrow starting
about 6 months from natural exposure to vectors.9
Once bone marrow has been colonized, it is generally
accepted that the dog is persistently infected. However,
a fraction of dogs with positive bone marrow PCR may
become negative in the following months without any
treatment; it is unknown whether in these dogs the
parasite density falls below the threshold limit of the
PCR test, amastigotes persist in other organs, or the
infection is actually eradicated by host defense mecha-
nisms.9 While most dogs develop an antibody response
shortly after the first contact with the leishmania para-
site, resistance or susceptibility to progressive infection
depends on the balance between T helper 1 (Th1) (cell-
mediated) and T helper 2 (Th2) (humoral) immune
responses. Specifically, dogs with a predominant Th2
response are likely prone to parasite dissemination to
multiple tissues and overt clinical signs, while dogs
with a predominant Th1 response may keep the para-
site in check and be clinically healthy.10–13 Hence, the
presence of circulating antibodies does not necessarily
imply that the dog is suffering clinical leishmaniasis,
and the presence of amastigotes in tissue can be noted
in clinically healthy dogs. Therefore, the guidelines for
diagnosis and staging of canine leishmaniasis, released
by the Canine Leishmaniasis Working Group
(CLWG)14, suggest a combination of clinical and labo-
ratory criteria for the classification of dogs into
exposed, infected, or actually sick animals:
1) Exposed dogs: dogs that are clinically unremark-
able, have a low-titer positive serology, and are
negative by PCR and/or cytology.
2) Infected dogs: dogs that are clinically unremark-
able, with normal hematology and clinical chem-
istry variables, but positive PCR and/or cytology in
bone marrow, lymph node, spleen, skin, or periph-
eral blood.
3) Sick dogs: infected dogs with typical clinical or clini-
copathologic changes.
4) Severely sick dogs: sick dogs with a severe clinical
condition such as proteinuric nephropathy, chronic
renal failure, and with concurrent problems that
may or may not be related to leishmaniasis, such as
ocular disease causing blindness and severe joint
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disease impairing motility, and which require
immunosuppressive treatment. These dogs include
also animals with potential concomitant conditions
such as coinfections or neoplastic, endocrine, or
metabolic diseases, or those that are unresponsive
to repeated courses of antileishmanial treatments.
Alternative guidelines released by the expert
group known as Leishvet classify sick dogs in 4 differ-
ent stages according to the severity of clinical signs,
clinicopathologic findings, and serologic status.15
Clinical Signs of Canine Leishmaniasis
The interpretation of clinicopathologic, serologic, and
molecular tests should take into account the history
(eg, exposure to phlebotomine vectors), signalment
(male dogs > 2 years are at high risk), and clinical
presentation. The latter is characterized by awide spec-
trum of clinical presentations, ranging from infections
characterized by the absence of overt clinical findings
in the presence of obvious laboratory abnormalities, to
more or less marked clinical and laboratory abnormali-
ties that may require hospitalization, especially in cases
with severe life-threatening complications.14–26
Laboratory Abnormalities thatmay Support
or Confirm Leishmaniasis
In addition to some typical clinical findings, laboratory
abnormalities uncovered by routine hematology, clini-
cal chemistry, or urinalysis may support the clinical
suspicion of canine leishmaniasis. Moreover, espe-
cially in the early phases of leishmaniasis, some labora-
tory changes may raise suspicion in the absence of
obvious abnormal findings at physical examination.
The basic mandatory panel of tests and their signifi-
cance for the classification of clinically suspect dogs or
dogs with positive PCR and/or cytology indicating
presence of amastigotes are summarized in Table 1.
Hematologic abnormalities
Hematologic changes in canine leishmaniasis are non-
specific.27 Neutrophilia, due to a systemic inflamma-
tory response, may be present and particularly
prominent in cases with ulcerative cutaneous lesions
and secondary bacterial infection.27,28 Conversely,
quantitative or qualitative morphologic changes in the
other leukocyte populations are less common,
although lymphopenia, lymphocytosis, or eosinophilia
are occasionally described28–30 Amastigotes are rarely
documented in circulating neutrophils, lymphocytes,
and monocytes of infected dogs (< 0.5% of cases).29,31
As the percentage of infected cells is so low, a micro-
scopic search in peripheral blood smears is generally
not rewarding. Rather, in cases of systemic disease and
suspected peripheral blood dissemination, the test of
choice is PCR/quantitative PCR as it is more sensitive
(see below).
The most common hematologic change in canine
leishmaniasis is a mild to moderate normocytic
normochromic anemia, an anemia of chronic
disease.27,28,32,33 However, the pathogenesis of anemia
in leishmaniotic dogs includes additional mechanisms
such as reduced erythropoietin synthesis due to renal
failure. Moreover, it is very likely that the anemia also
has a hemolytic component as suggested by a positive
Coombs test in a minority of cases.34 The latter may be
associated with a “lupus-like” reaction along with
other clinical or laboratory changes, such as a positive
anti-nuclear antibody (ANA) test35 or the presence of
perinuclear anti-neutrophil cytoplasmic autoantibod-
ies.36
Mild to moderate thrombocytopenia is fairly fre-
quent in leishmaniotic dogs without concurrent infec-
tions. In cases with marked thrombocytopenia, co-
infectionwith other vector-borne pathogens (eg, Ehrli-
chia canis, Anaplasma phagocytophilum, or A platys) or
other possible causes of reduced platelet concentration
should be suspected. The most likely mechanism
responsible for thrombocytopenia in leishmaniasis is
an immune-mediated peripheral destruction of circu-
lating platelets, as anti-platelet antibodies have been
demonstrated in leishmaniotic dogs.33,37,38
In addition, platelet loss may be associated with
hypercoagulability caused by a decreased concentra-
tion of antithrombin III due to protein-losing
nephropathy39 (see below). Disseminated intravascu-
lar coagulation (DIC) has been occasionally reported in
leishmaniotic dogs.40 However, thrombocytopenia in
leishmaniotic dogs can also be due to suppressed plate-
let production in the bone marrow. Finally, reduced
platelet function has been described in dogs with nor-
mal platelet concentrations in canine leishmaniasis41,
although this reduced function is rarely responsible for
hemostatic abnormalities.
Immunophenotyping of lymphocytes
Flow-cytometric determination of the CD4/CD8 lym-
phocyte ratio in peripheral blood of dogs infected with
Leishmania sp. has been evaluated with the rationale
that a decreasing Th1 response and consequent
554 Vet Clin Pathol 45/4 (2016) 552–578©2016 American Society for Veterinary Clinical Pathology
Laboratory diagnosis of leishmaniasis Paltrinieri et al
increased susceptibility to overt clinical leishmaniasis
is accompanied by a lower CD4/CD8 ratio due to
decreased CD4+ lymphocyte numbers.42,43 Therefore,
a seropositive or PCR-positive dog with a low CD4/
CD8 ratio is expected to be more predisposed to
develop clinical signs than a similar dog with a CD4/
CD8 ratio in the reference range. However, due to the
high individual variability, the definition of a cutoff for
proper clinical staging is difficult. Hence, the CD4/CD8
ratio may be more suitable for monitoring the post-
treatment follow-up rather than initial staging of dogs
suspected to have leishmaniasis.
Bonemarrow evaluation
The hematologic profile of leishmaniotic dogs may be
complemented by bone marrow cytology17,30,32,44,
whichmay be highly diagnostic just by themicroscopic
identification of amastigotes in macrophages. In addi-
tion, the quantitative assessment of the frequency of
infected macrophages in a bone marrow smear may
allow differentiation between an infected and a sick
dog14, as the parasite load and the magnitude of cyto-
logic alterations are generally more prominent in dogs
with clinical signs45, although some histologic studies
demonstrated that parasite density can be high despite
few clinical signs.46 Therefore, rare infected macro-
phages may occasionally be seen in the absence of
other pathologic or clinical findings in infected dogs,
whereas sick dogs are expected to have higher num-
bers of parasites and abnormal bone marrow findings.
The latter would include erythroid hypoplasia with
normal proportions of proliferating and maturing
pools28, but occasionally associated with myeloid
hyperplasia and an increased myeloid-to-erythroid
(M:E) ratio. Moreover, bone marrow inflammation or
myelitis47 is usually present (Figure 1). This includes
an increased number of infected or noninfected
macrophages, often accompanied by erythro- or
cytophagia, increased numbers of mature segmented
Table 1. Summary of typical, frequent, and occasional laboratory findings in canine leishmaniasis.
Typical Abnormalities Frequent Abnormalities Occasional Abnormalities
Routine CBC—leukogram Neutrophilia27,28 Lymphopenia;
Lymphocytosis;
Eosinophilia28–30
Routine CBC—erythrogram Normocytic normochromic
nonregenerative anemia
Positive Coombs test or
anti-RBC antibodies34
Routine CBC—thrombogram Thrombocytopenia (check
for coinfections)37,38
Bone marrow cytology Erythroid hypoplasia;
Myeloid hyperplasia;
Macrophage proliferation-hyperplasia;
Presence of intracytoplasmic
amastigotes;
Plasmacytosis17,28,30,32,44–48
Megakaryocyte hyperplasia;
Secondary dysmyelopoiesis
(dyserythropoiesis or
dysmegakaryopoiesis,
occasionally dysgranulopoiesis)28,48
Hemostasis Decreased Antithrombin III Prolonged PT and APTT40
Hypercoagulability
detected by
thromboelastography or
thromboelastometry49
Routine clinical chemistry Renal Azotemia14–17,34,65,67–70,78,80
Hyperproteinemia with hypoalbuminemia
and inverted A:G ratio14,15,65,81,103–105
Abnormalities in other
biochemical analytes
(depending on affected
tissue)16,27,53–57,174
Serum protein electrophoresis Polyclonal gammopathy14,15,65,81,103–105 Oligoclonal gammopathy108 Mono- or biclonal
gammopathy106,107,109,110
Acute phase proteins and
other markers of inflammation
Increased C-reactive protein,
serum amyloid A, haptoglobin,
ceruloplasmin, Ferritin; decreases
of total iron-binding capacity111–116
Decreased PON-1 and
high-density lipoprotein117–119
Urinalysis Proteinuria; decreased urine specific
gravity14–16,34,81; mixed proteinuria
in SDS-electrophoresis94–97
Increased markers of
renal tubular damage
(c-glutamyl transferase
and N-acetyl-b-N-glucosaminidase)96,100
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neutrophils, and a moderate to marked plasmacytosis
characterized by a higher number of plasma cells, mott
cells, and lymphocytes.28,32,48 Megakaryocyte hyper-
plasia can also be present, especially when peripheral
consumption of platelets occurs.
Albeit less frequent, secondary dysmyelopoiesis
can be found and is characterized by peripheral cytope-
nia (eg, anemia and thrombocytopenia) associated
with hypercellular bone marrow displaying signs of
asynchrony and dysplastic features (Figure 2). In
canine leishmaniasis, these mostly include dyserythro-
poiesis with abnormal mitoses, asynchronous
nucleo-cytoplasmic maturation, nuclear fragmenta-
tion, and/or late-stage maturation arrest and dys-
megakaryopoiesis with dwarf megakaryocytes and
emperipolesis, while dysgranulopoiesis with abnormal
A B
C D
E F
Figure 1. Canine bone marrow smear summarizing the main findings in canine leishmaniasis. May–Gr€unwald–Giemsa. (A–C) Bar = 15 lm. (D and F)
Bar = 20 lm. (E) Bar = 70 lm, (A) Several Leishmania sp. amastigotes in the cytoplasm of infected macrophages. (B, D, F) Free amastigotes in the back-
ground (arrows). (C) Infected macrophage with erythrophagia. (D) Infected macrophage with cytophagia. (E) Myeloid hyperplasia, erythroid hypoplasia,
and infected macrophages. (F) Marked plasmacytosis, myeloid hyperplasia, and a Mott cell.
556 Vet Clin Pathol 45/4 (2016) 552–578©2016 American Society for Veterinary Clinical Pathology
Laboratory diagnosis of leishmaniasis Paltrinieri et al
maturation of granulocytes and ring forms is rather
rare.28,48 Therefore, the presence of secondary dys-
myelopoiesis is per se not diagnostic for leishmaniasis
except in the presence of amastigotes, and primary
myelodysplastic syndromes should be carefully ruled
out based on serology and PCR.
Hemostatic abnormalities
Hemostatic abnormalities are uncommon in leish-
maniotic dogs. Activated partial thromboplastin time
and prothrombin time may be prolonged; however in
most cases, this is likely due to preanalytic factors
such as an increased concentration of total globulins,
which is frequent in dogs with leishmaniasis. Alterna-
tively, prolonged coagulation times may result from
DIC, although this complication is uncommon in
leishmaniotic dogs.40
Conversely, hypercoagulability may be com-
mon in leishmaniotic dogs if affected by severe
protein-losing nephropathy. This is mostly due to
glomerular loss of ATIII, a protease inhibitor
involved in the regulation of blood coagulation
that prevents the conversion of fibrinogen into fib-
rin. The lack of this physiologic anticoagulant may
induce hypercoagulability that in turn promotes
thrombosis and subsequent consumption coagu-
lopathy.49 Antithrombin III concentration can be
measured by immunoturbidimetic methods, and is
particularly recommended in dogs with protein-los-
ing nephropathy.
The hyperviscosity syndrome due to the increased
circulating globulins also favors hypercoagulability.
Hypercoagulability in leishmaniotic dogs was also
demonstrated through a shorter clot formation time
and increased global clot strength using
A B
C D
Figure 2. Canine bone marrow smear with secondary dysmyelopoiesis associated with leishmaniasis, May–Gr€unwald–Giemsa. (A and B) Bar = 20 lm.
(C and D) Bar = 60 lm. (A) Atypical mitotic figure and infected macrophage. (B) Myeloid hyperplasia, plasmacytosis, and atypical mitosis and asyn-
chrony in an erythroid precursor (arrowhead). (C) Dwarf megakaryocytes; (D) Emperipolesis in a megakaryocyte. (A and C) Free amastigotes in the back-
ground (arrows).
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thromboelastography (TEG).49 In contrast, the clot for-
mation of leishmaniotic dogs assessed by thromboelas-
tometry (TEM, a technique similar to TEG) was within
normal limits in another report.50 It is worth noting
that TEM and TEG are affected by the RBC mass51,52,
which possibly explains the different results obtained
by TEM and TEG.
Biochemical abnormalities
The clinical presentation of dogs with leishmaniasis is
quite variable, and the type of biochemical abnormali-
ties varies accordingly. Renal dysfunction and inflam-
mation and/or immune reactions are relatively
frequent; therefore, the respective analytes should be
evaluated in each dog with suspected or confirmed
leishmaniasis. Likewise, biomarkers of hepatobiliary or
pancreatic dysfunction may be altered in cases with
pyogranulomatous infiltrates in these organs.14,16
Activities of enzymes released from affected skeletal
muscle such as CK and LDH can also increase.53 The
activity of the brain isoenzyme of CK can be increased
in the presence of neurologic signs54 due to Leishma-
nia-related cerebrovascular alterations55,56, while
increases in the myocardial isoenzyme of CK can occur
with cardiomyopathy. In such latter cases, increased
troponin I has also been reported.27,57 Abnormal endo-
crine variables are rare, although amastigotes and
inflammatory lesions have been found in the adrenal
cortex of leishmaniotic dogs.58,59
Assessment of renal function
The deposition of circulating immune complexes at
the glomerular level induces inflammatory
changes detectable histologically and ultramicroscopi-
cally26,60–62, leading to a proteinuric nephropathy.62
The resulting chronic kidney disease (CKD) is charac-
terized by glomerulosclerosis, renal hypertension, and
tubulointerstitial nephritis.61,62 Advanced stages of
CKD are characterized by azotemia and may be
associated with systemic hypertension, both factors
contributing to comorbidity in dogs with leishmania-
sis.62,63 Therefore, the clinical and laboratory approach
to leishmaniotic dogs with proteinuric nephropathy is
the same as the one recommended by the Interna-
tional Renal Interest Society (IRIS)64 for any type of
CKD. This approach is based on a thorough clinical
evaluation including the measurement of arterial pres-
sure, and on the quantification of urinary proteins and
of markers of renal function such as the urine specific
gravity and the serum concentration of creatinine.64
This latter increases frequently in leishmaniotic
dogs.14–16,34,65 However, creatinine is not sensitive
enough to detect the earliest stages of renal insuffi-
ciency66, and research is currently underway to iden-
tify early markers for decreased glomerular filtration
rate (GFR), either in leishmaniotic dogs or in dogs
affected by other types of CKD. The direct measure-
ment of GFR through clearance tests would be the best
method to assess real-time functionality of the kid-
neys.67 The serum concentration of Cystatin C (Cys C)
has been assessed in dogs with leishmaniasis68, but in
contrast to other types of early CKD69, Cys C was not a
good marker in dogs with leishmaniasis.70 Recently,
symmetric dymethilarginine (SDMA) has been pro-
posed as an early biomarker for early diagnosis of
CKD.71,72 Currently, there are no studies on the diag-
nostic power of SDMA in early CKD in leishmania-
affected dogs that have proteinuria in the presence of
normal creatinine concentrations.
Other serum markers may provide additional
information in leishmaniotic patients with CKD. For
example, in people, the increased serum concentration
of homocysteine (Hcy), endothelin-1 (ET-1), or C-
reactive protein (CRP) may predict hypertension and/
or inflammation associated with CKD.73–76 Increases
of Hcy and ET-1 also have been reported in dogs with
CKD, some of which were affected by leishmania-
sis.77,78 However, further studies are needed before
these markers can be recommended as ancillary tests
for the management of leishmaniotic dogs with CKD.
Conversely, inflammatory markers such as CRP,
ferritin, and adiponectin may increase in the urine of
leishmaniotic dogs, sometimes in the absence of
elevated serum creatinine.70,79,80 However, their
increase is usually due to a systemic inflammatory
state rather than to CKD. Finally, tubulointerstitial
dysfunction may develop secondarily to proteinuria
caused by glomerular damage in leishmaniotic dogs.
Markers of tubular injury in urine are described in the
section on urinalysis.
Abnormalities of urinalysis
As for any suspected proteinuric nephropathy, it is
necessary to confirm CKD, proteinuria, and tubular
damage not only by serum chemistry but also by
urinalysis.14–16,34,81
Physico-chemical analysis. Urine specific gravity (USG)
tends to decrease in dogs with tubulointerstitial dam-
age due to loss of concentrating function and should be
assessed by a refractometer on urine that has previ-
ously been centrifuged.66 The supernatant should be
tested with a urine dipstick to provide the pH and the
concentration of proteins, keeping in mind that an
overestimation of proteinuria can occur with alkaline
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urine (pH 8).66 The presence of glucose is a potential
indicator of tubular damage.
Sediment analysis is another important compo-
nent in the evaluation of leishmaniotic dogs, as an
active sediment (eg, presence of high numbers of
leukocytes, erythrocytes, or bacteria) may indicate a
lower urinary tract infection superimposed on the pri-
mary disease (leishmaniasis) and may also result in
overestimation of proteinuria.82 The presence of gran-
ular or cellular casts may be consistent with tubular
damage.66
Evaluation of proteinuria. The evaluation of protein-
uria is mandatory, as proteinuria is a risk factor
for the progression of nephropathy.83 According to
the guidelines by the American College for Veteri-
nary Internal Medicine (ACVIM)84, proteinuria
should be assessed in any dog suffering from a
predisposing disease, such as leishmaniasis. This
assessment includes certain recommended standards
such as collection by cystocentesis to avoid con-
tamination from the lower urinary tract. However,
a first screening may be done on voided samples,
as results recorded with the 2 methods of collec-
tion overlap when the sediment is inactive.85
Proteinuria may be first investigated using a dip-
stick, and if the result is negative, the dog is likely
nonproteinuric according to the IRIS classification64
and no further evaluation of proteinuria is neces-
sary.86 In contrast, if the dipstick is weakly positive
in dogs with low USG, or strongly positive regard-
less of USG, the dog is likely proteinuric. In this
latter case, in order to classify the level of protein-
uria, the urinary protein-to-creatinine (UPC) ratio
must be determined. Nonproteinuric dogs have a
UPC ratio < 0.2, borderline proteinuria ranges from
0.2 to 0.5, and proteinuric dogs have a UPC ratio
> 0.5 according to the IRIS classification (recently
revised for the diagnosis of glomerular disease).64,87
In the interpretation of borderline results, particu-
lar attention should be paid to potential analytic
factors that can influence the UPC ratio such as
type of reagent, methods, or instruments.88–90
Quantification of proteinuria must be repeatedly
assessed (3 times in 2 weeks84 or once on pooled
urine91) because additional investigations or treat-
ments should only be pursued if proteinuria is persis-
tent.84–87 Finally, the origin of urinary protein should
be assessed by a histologic examination of a renal
biopsy.84 However, according to the recent IRIS guide-
lines87, renal biopsy is recommended only in the case
of rapid progression of CKD or in dogs not responding
to conventional treatments. Alternatively, the origin
of proteinuria can be argued on the basis of surrogate
methods such as qualitative analysis of urinary pro-
teins (see below).
Markers of tubular injury. In order to stage dogs with a
tubular component of proteinuria and advanced renal
disease, urinarymarkers may be used.92 Some conven-
tional markers such as granular or cellular casts and
glycosuria in normoglycemic dogs are very specific
indicators of tubular damage, but are not sensitive
enough to detect dogs with early tubular damage and
are rarely observed in leishmaniotic dogs. Sodium
dodecylsulphate (SDS) electrophoresis of urinary pro-
teins or measurement of more recently defined urinary
markers may provide an earlier indication of tubular
damage.
The SDS-mediated denaturation and negative
charge of urinary proteins allows mass-dependent
migration during polyacrylamide gel (SDS-PAGE) or
agarose gel (SDS-AGE) electrophoresis.93 This differ-
entiates large proteins present in urine due to glomeru-
lar damage, from small proteins of tubular origin.
Results of SDS-PAGE or SDS-AGE correlate well with
histopathology of renal biopsies, especially for the dif-
ferentiation between glomerular and severe tubuloint-
erstitial damage.94,95 Using SDS-AGE, it has been
shown that leishmaniotic dogs have a mixed glomeru-
lar and tubular pattern. Only a minority of dogs, likely
those with early CKD, have a pure glomerular protein-
uria.60,96 However, SDS-AGE may not be accurate
with very concentrated or diluted urine.97 Occasion-
ally, lowmolecular weight proteinuria with no signs of
glomerular disease may be seen, possibly due to free
light chain proteinuria (prerenal proteinuria associated
with highly activated antibody production) rather
than to tubular damage.98
Enzymuria is considered a good marker of tubular
damage. Specifically, the enzymes of interest are
located in the cytoplasm of tubular epithelial cells and
may be found in urine when integrity of tubular cells
has been disturbed. The 2 most popular urinary
enzymes are GGT and N-acetyl-b-N-glucosaminidase.
They are both unstable in untreated urine and their
activity must be measured immediately after sam-
pling.99 Increases of these and other enzyme activities
(eg, ALP or b-glucuronidase) have been reported in
dogs with leishmaniasis100, and the increase of GGT
correlates with the presence of tubular bands in SDS
electrophoresis of urine.96 In contrast, no information
is available on the utility in leishmaniotic dogs of the
measurement of other urinary analytes used to detect
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tubular damage in dogs with CKD not associated with
leishmaniasis.92,101,102
Assessment of inflammatory/immune reactions
Leishmaniotic dogs with overt disease mount an
intense inflammatory response and produce signifi-
cant amounts of various molecules involved in the
immune response, including antibodies. There are sev-
eral tests including serum protein electrophoresis or
measurement of APP to assess and monitor these
mechanisms.
Serum protein analysis including electrophoresis
may reveal abnormalities very early during the course
of the disease.17 For instance, total proteins and total
globulins are frequently increased14,15,65,81,103, and
the increase of total proteins has been shown to corre-
late with the severity of the clinical score.104 The only
exception is albumin, which decreases because it is a
negative APP (see below) but can also be lost due to
proteinuric nephropathy, resulting in a decreased
albumin-to-globulin (A/G) ratio.65,103 The decrease of
the A/G ratio is so frequent that it has been considered
by some authors to be one of the most sensitive tests
for canine leishmaniasis103, and hypoalbuminemia is
considered a negative prognostic factor in leishmani-
otic dogs.105 The typical electrophoretogram of
leishmaniotic dogs with overt clinical signs (Figure 3)
displays hypoalbuminemia, a moderate increase of a2-
globulins, which include most of the positive APP, and
a marked increase of c-globulins, due to the high titers
of circulating antibodies, immune complexes, and
other molecules with c-globulin-like mass and charge.
Occasionally, peaks of circulating antibodies are found
in the b region, where IgM and some APP migrate. The
gammopathy in leishmaniasis is typically polyclonal
but sometimes the peak may appear narrower (ie,
oligoclonal), biclonal106, or definitely monoclonal107,
especially using capillary zone electrophoresis (Fig-
ure 4).108 However, although monoclonal peaks asso-
ciated exclusively with leishmaniasis have been
described, the presence of monoclonal peaks should
also include consideration of concurrent disease
such as other vector-borne diseases or multiple
myeloma.109,110
Acute phase proteins are powerful indicators of
inflammation. Pro-inflammatory cytokines elicited
during an acute phase response stimulate the
release of neutrophils from storage pools, activate
myelopoiesis, and modulate protein synthesis in the
liver.75 This latter phenomenon leads to a decreased
serum concentration of negative APP and an
increased concentration of the positive APP that
A B C
D E F
Figure 3. Examples of electrophoretograms from a normal dog (A) or dogs with clinical leishmaniasis (B–F) using agarose gel electrophoresis. (A) Nor-
mal canine electrophoretogram for comparison (a = albumin; a1, a2, b1, b2, c = globulin fractions); (B) Marked increase of a2- and c-globulins, with poly-
clonal gammopathy. (C) Mild increase of a2-globulins (detectable only in the early phase of the disease). (D) Severe hypoalbuminemia and polyclonal
gammopathy. Also b2-globulins are likely increased in this case. (E) Marked increase of a2-globulins and polyclonal gammopathy, with a prominent peak
in the b2-region and a less evident polyclonal peak in the c-region. (F) Marked hypoalbuminemia and oligoclonal gammopathy. This dog was co-infected
with Ehrlichia canis.
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includes a series of immunomodulators, scavenger
or transport proteins, antiproteases, and other pro-
teins involved in host defenses. Therefore, it is not
surprising that the serum concentration of positive
APP is high in dogs with overt canine leishmania-
sis. The list of APP whose concentration increases
in serum of leishmaniotic dogs is long and includes
CRP, haptoglobin (Hp), ceruloplasmin (Cp), serum
amyloid A (SAA), and ferritin.111–116 Similarly, a
decrease of negative APP other than albumin has
also been reported. They include transferrin (total
iron-binding capacity or TIBC) that results in a
reduction of iron, and a decreased activity of the
enzyme paraoxonase 1 (PON-1).113,117,118 Paraox-
onase 1 is a negative APP that is bound to high-
density lipoproteins (HDL) and represents a link
between inflammation and oxidative stress.
Decreased PON-1 activity is not always seen in
leishmaniotic dogs, but it may become evident
when oxidative stress is particularly severe.117 In
these cases, the concentration of HDL, which is
converted into low-density lipoprotein (LDL) after
detachment from PON-1, also decreases118 and may
prove an inexpensive marker of inflammation and
oxidative stress associated with leishmaniasis.
Recently, reduced serum activity of adenosine
deaminase and butyrylcholinesterase, 2 enzymes
involved in modulating immune responses, have
also been reported in dogs with leishmaniasis.119
The APP changes summarized above are not diag-
nostic per se as mild increases of positive APP have been
reported also in infected dogs without clinical signs114,
and markedly increased levels may occur in diseases
other than leishmaniasis.75 In a dog with confirmed
leishmaniasis, however, the magnitude of APP
changes may reflect the extent of the systemic inflam-
matory response and thus provide prognostic informa-
tion. In particular, decreased PON-1 activity may be a
negative prognostic indicator.
Tests for Etiological Diagnosis thatmay
Support or Confirm the Diagnosis of
Leishmaniasis
Tests for an etiologic diagnosis are used to confirm the
presence of the parasite or its components (direct tests)
or of the host’s response to the parasite (indirect tests).
As previously mentioned, positive indirect tests (ie,
serology) may or may not indicate a current infection.
Conversely, positive direct tests (cytology, histology,
immunohistochemistry, PCR, culture, and xenodiag-
nosis) demonstrate that the dog is actually infected
with Leishmania sp. The diagnosis of an actual presence
of disease has to rely on clinical findings and clinico-
pathologic tests. The most common tests for etiologic
diagnosis are discussed below.
Serology
Methods
There are techniques such as Western blotting that
is highly accurate but not available in routine prac-
tice, while others have been proposed but are not
extensively used, such as the latex agglutination
test or detection of antibodies through immunosen-
sors or flow cytometry.120–123 The most common
techniques used to detect antileishmanial antibodies
are based on 3 analytic principles: immunofluores-
cent antibody test (IFAT), enzyme-linked
immunosorbent assay (ELISA), and immunochro-
matographic test (ICT). The latter method is the
basis of all rapid in-clinic assays, which only pro-
vide a qualitative result (ie, presence/absence of
specific reactive bands or spots).124 Several com-
mercial ICT kits are available, which are based on
single or multiple recombinant Leishmania sp. anti-
gens to be incubated with serum, plasma, whole
blood, or blood spots dried onto filter paper.125 The
Figure 4. Comparison of electrophoretograms from dogs with clinical
leishmaniasis, with agarose gel electrophoresis (AGE, A and C) or with
capillary zone electrophoresis (CZE, B and D). The electrophoretograms
in A and B are from the same sample of a dog with leishmaniasis. The
electrophoretic profile is similar, but in CZE the hypoalbuminemia is more
evident and the c-globulin peak is narrower, suggesting a false diagnosis
of oligo- or monoclonal gammopathy. The electrophoretograms in C and
D are from the same sample of a dog with leishmaniasis. In this case, the
c-globulin peak is higher in CZE than in AGE, suggesting a biclonal origin,
with a very narrow subpeak on the right side of the c-globulin fraction,
indicating a possible monoclonal component.
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specificity of these tests is quite acceptable, but sen-
sitivity is usually low (in the approximate range of
30–70%) and largely dependent on leishmaniasis
stage.126 Lowest test sensitivity is associated with
infected dogs without clinical signs, the highest
ones with dogs with overt disease.127 Therefore,
ICT may be used as a first in-clinic test to complete
the laboratory evaluation of clinically suspect dogs.
In case of a positive result, a quantitative serology
(ELISA or IFAT) should be performed to obtain a
numeric result. Also, due to its low sensitivity, a
negative ICT in light of strong clinical signs should
be questioned, and followed up by IFAT or ELISA.
Recently, an ICT kit claiming detection of antibod-
ies developed after natural infection but not those
elicited by vaccination with the LiESP-based vaccine
has been proposed as a tool to differentiate vacci-
nated from infected dogs.128 The principle of the
test is sound, and a preliminary study reported a
high sensitivity of this ICT format129, while a
further study reported a low sensitivity.130
The IFAT is considered the reference method
for anti-Leishmania serology in dogs126–131 based on
the high sensitivity and specificity (near 100% for
both) except in areas endemic for the New World
parasite Trypanosoma cruzi that may give false-posi-
tive results. The ELISA is also very sensitive and
specific when a combination of immunodominant
recombinant proteins is used as antigen, whereas it
has slightly lower specificity when crude parasite
lysates are employed instead.124,130–132 In
comparison with the IFAT that is based on the
operator-dependent evaluation of promastigote flu-
orescence by UV microscopy, the ELISA is easier to
standardize as results are read by an automated
spectrophotometer. Both IFAT and ELISA have the
advantage of providing quantitative results reflect-
ing the final antibody titer (the last 2-fold serial
dilution of sample providing a positive result) or,
for ELISA only, optical density values converted
based on a reference titered sample. Owing to the
unavoidable variability due to operator-dependent
or analytic factors (antigen stability, antiserum, or
equipment performances), reference sera with stan-
dardized anti-Leishmania antibody titers are not
universally available. At this point, a titer is con-
sidered high if it is 4-fold higher than the thresh-
old value of the laboratory.14 Similarly, 4-fold titer
variations in sequential samples of the same dog
should be expected with seroconversions, or with a
positive therapy outcome. Hence, sequential sam-
ples must always be analyzed by the same method
and in the same laboratory.
Interpretation
Serologic tests detect and quantify antibodies pre-
sent in serum or plasma. As not every dog will
seroconvert after infection, it is difficult to precisely
determine seroconversion in naturally infected dogs.
Antibodies can be found in blood as early as one
month after exposure to infected phlebotomines;
the median time for seroconversion was estimated
to be about 5 months in natural conditions and
3 months in experimental studies using artificial
infection.133 Therefore, dogs living in highly
endemic regions may seroconvert during the active
period of the sand fly (from late spring to early
autumn in temperate zones, all year in tropical
areas).9 If the vector-transmitted parasites are effi-
ciently controlled by the host’s immune response,
the antibody titers, if present, tend to remain low
and therefore these clinically healthy dogs can be
classified as exposed (when the infection is not
confirmed by direct tests) or infected.14 Conversely,
uncontrolled parasite dissemination is associated
with an exaggerated humoral response. Antibody
titers will be high when the disease is evident in
dogs classified as sick or very sick by CLWG classifi-
cation14 or stage II, III, or IV (mild, severe, or very
severe disease) by the Leishvet classification.15
While a direct relationship between the clinical
score and antibody titers exists104,134, low-to-med-
ium antibody titers may also be detected in dogs
with clinical signs. These have been classified as
stage I or II (mild or moderate disease) according to
the Leishvet classification.15
In conclusion, quantitative serology should be
always be performed when, despite strong clinical sus-
picion of leishmaniasis, lesions approachable by fine-
needle aspiration are not present or when cytologic
analysis of lesions, lymphoid organs, and bonemarrow
fail to reveal the typical pattern associated with leish-
maniasis, despite a possible PCR-positivity. In this case,
a high antibody titer is often consistent with leishma-
niasis, while, if the antibody titer is low, leishmaniasis
should be considered only if other diseases potentially
responsible of the clinical presentation have been ruled
out.14,15
The increasing use in southern Europe of the
LiESP vaccination, known to elicit long-standing low-
to-medium titers of antileishmanial antibodies, may
further complicate the interpretation of serology in
vaccinated dogs. Practical laboratory protocols allow-
ing discrimination between the humoral response in
Leishmania-infected and LiESP-vaccinated dogs are not
yet available.
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PCR
Methods
Several methods have been proposed to detect the
presence of parasite DNA in various biologic samples.
Some of these methods are not commonly used or
were not recently validated, such as those based on
the use of probes labeled with gold nanoparticles135
or the loop-mediated isothermal amplification
(LAMP).136 Conversely, conventional PCR, nested
PCR, and quantitative (real-time) PCR are widely
used in routine practice.14,15,126,131 Sensitivity and
specificity vary according to the method and the tar-
get DNA sequence. Most of the PCR tests currently
used are targeting multicopy DNA sequences, such
as the small subunit ribosomal RNA genes or the
kinetoplast DNA minicircles, thus increasing the sen-
sitivity of the test.137 Compared with conventional
and nested PCR, the quantitative PCR techniques
offer 2 main advantages138: they may be run in
closed systems and are therefore less prone to con-
tamination, and they provide information about the
copy number of DNA present in the sample. This lat-
ter aspect may be relevant during the follow-up to
monitor the efficacy of leishmanicidal treatments,
and therefore it may be advisable to use quantitative
PCR at first diagnosis (before any treatment) for the
establishment of a baseline value for comparison of
future results during the follow-up.138,139 Overall, it
does not seem that quantitative PCR techniques are
more sensitive than conventional or nested PCR to
diagnose canine leishmaniasis.140 One additional lim-
itation of quantitative PCR is that standardized meth-
ods to accurately quantify the DNA copies may not
be offered by some laboratories.
Samples
Polymerase chain reaction techniques may be
applied virtually on any tissue or biologic fluid.
Theoretically, it may be superfluous to use molecu-
lar tests in affected tissues in which Leishmania
amastigotes have been visualized by cytology or
histology. However, these latter methods are less
sensitive than PCR and therefore, a negative cyto-
logic result does not exclude that a low number of
amastigotes is indeed present. Hence, when a fine-
needle aspirate or a tissue biopsy is performed, it
may be advisable to prepare cytologic or histologic
specimens and to store the remaining material in
the preservatives recommended by the laboratory
to run PCR. If needed, PCR may also be performed
on cytologic material already fixed on glass slides141
or on formalin-fixed and paraffin-embedded
material.142,143
In routine practice, PCR is rarely run on biopsies
from lesions for which cytology and histology are pre-
ferred, but rather if cytology and histology are not
diagnostic. When there are no lesions eligible for fine-
needle aspiration or biopsy (eg, when the only preva-
lent clinical symptoms include anemia or proteinuric
nephropathy), bone marrow and/or lymph nodes and
spleen are the tissues with the highest potential preva-
lence for detection by PCR, especially in sick
dogs15,144–148, provided that the quality of the sample
is adequate. Recent studies demonstrated that con-
junctival and, to a lesser extent, oral and nasal swabs
are very sensitive for the detection of Leishmania DNA
and, in addition, can provide positive results earlier
than other tissues.144,146,149–152 Whole blood or buffy
coats may also be used for conventional or quantitative
PCR analysis. The sensitivity is lower than in the above
tissues, but blood collection is less invasive, and when
positive, provides a rapid and inexpensive diagno-
sis.14,15
Interpretation
When interpreting PCR results, the difference
between infected and sick dogs must be kept in
mind. Ultimately, the detection of the parasite’s DNA
indicates that the dog is infected. The correlation
between infection and disease must then be based on
the presence of clinical and laboratory abnormalities.
From this perspective, the detection of Leishmania
DNA in lesions with cytologic or histologic patterns
highly consistent with leishmaniasis, or in blood or
bone marrow of a dog with systemic signs of leish-
maniasis supports the diagnosis of disease. Con-
versely, positive PCR results in dogs without signs
clearly referable to leishmaniasis do not support the
hypothesis that the infected dog is also affected by
clinical leishmaniasis, unless any other possible dis-
ease is excluded. For example, a transient PCR-posi-
tivity in bone marrow may be found a few months
after the natural exposure to sand fly bites, without
necessarily meaning that the dog is definitively
infected or even sick.9 Similarly, PCR-positivity in
intact skin of dogs frequently exposed to vectors does
not necessarily mean that dermal “contamination”
by infectious bites will be followed by systemic para-
site dissemination.10–13 Positive skin PCR results may
in fact depend on the presence of recently inoculated
promastigotes, or of amastigotes phagocytosed by res-
ident macrophages that, in resistant dogs, may effi-
ciently control (or even eliminate) the parasite on a
local level.144,148,153
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Cytology
Samples and methods
Fine-needle aspiration should be performed in all cases
with cutaneous papular or nodular lesions and/or
lymph node enlargement.14 Ulcerative cutaneous
lesions can be sampled by scraping the lesion or using
less invasive methods such as imprint smears. Addi-
tionally, reports describing the presence of amastigotes
and associated lesions in nodular masses with atypical
localization such as the tongue19,23, the testis154,155,
and oral or nasal masses156 have been reported. There-
fore, any nodular lesion in dogs with clinical or labora-
tory signs potentially consistent with leishmaniasis
(eg, anemia, CKD, alterations of the electrophore-
tograms, positive serology) should be sampled by fine-
needle aspiration. Nasal lesions may also be sampled
using brush cytology.157 Similarly, when clinical or
clinicopathologic patterns are consistent with leishma-
niasis, the possible presence of Leishmania should be
investigated also in pathologic body fluids such as joint
fluids158,159, effusions29, or cerebrospinal fluid (CSF),
although in this latter sample, cellularity is usually so
low that PCRmay detect the parasite better than cytol-
ogy.55 When cutaneous lesions, nodular lesions in
other organs, lymph node enlargement, or abnormal
accumulation of fluids are absent but the clinical suspi-
cion of leishmaniasis is high, the presence of parasites
should be investigated in tissues that contain many
cells of the monocyte-macrophage series, such as bone
marrow, lymph nodes, or spleen.14,15,44
Interpretation
Cytology aims to demonstrate the presence of Leishma-
nia amastigotes within the macrophages, or when the
parasite burden is high and cell lysis occurs, also in the
background (Figure 5). The detection of amastigotes
A B
C D
Figure 5. Examples of cytology specimens from dogs with Leishmania sp. infection. May–Gr€unwald–Giemsa. (A, C, D) Bar = 20 lm. (B) Bar = 15 lm.
(A) Imprint of an ulcerated skin lesion with pyogranulomatous inflammation (degenerate and nondegenerate neutrophils, macrophages, lymphocytes,
and plasma cells). Variably sized pigmented material likely resulting from cytophagia in the macrophage and in the background could be confused with
amastigotes. (B) Cytocentrifuged synovial fluid from a swollen joint. There are two amastigotes inside a large mononuclear cell with signs of nuclear
degeneration. Neutrophils and lymphocytes, indicating inflammation, are also visible. (C) Fine-needle aspirate of spleen with intracytoplasmic amastig-
otes, plasma cells, and neutrophils. (D) Fine-needle aspirate of a lymph node. No amastigotes are visible but in this case the diagnosis is supported by
the presence of reactive hyperplasia, characterized by variably sized lymphocytes, neutrophils, and plasma cells.
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may be difficult in ulcerative cutaneous lesions, where
necrosis and cellular debris or contaminating bacteria
may mask the presence of amastigotes. Attention
should be paid to not misinterpret cellular or granular
debris as amastigotes in such lesions.
The typical cytologic patterns associated with
leishmaniasis are usually characterized by granulo-
cytic-macrophagic or pyogranulomatous inflamma-
tion associated with a moderate to severe
lymphoplasmocytic infiltration in skin or nodular
lesions with atypical localization (Figure 5) and, in
lymph nodes, by a reactive hyperplasia of variable
degree, characterized by lymphoplasmacytic and
macrophagic infiltration, usually associated with
numerous neutrophils.44,160,161 Similarly, cytologic
patterns typically associated with leishmaniasis may be
found in the bone marrow, as described above. Neu-
trophils, lymphocytes and macrophages can also be
found in body fluids of dogs affected by leishmaniasis.
The diagnosis of leishmaniasis is easy when
amastigotes are detected in samples that show the
cytologic patterns described above. However, when
cytologic patterns consistent with leishmaniasis but no
amastigotes are seen, leishmaniasis should not be ruled
out, as it is known that the etiologic diagnostic sensitiv-
ity of cytology is low.126,131 In these cases, tests that
have higher analytic and diagnostic sensitivity, such as
PCR, must be run. Alternatively, affected tissues can be
biopsied to perform histology and immunohistochem-
istry, as described below. Conversely, when amastig-
otes are seen in the absence of cytologic abnormalities,
or cytology is done on bone marrow, lymph node, or
spleen, positive results must be interpreted carefully,
as systemic signs may be due to diseases other than
leishmaniasis.14 Similarly, a diagnostic workup to dif-
ferentiate sick from infected dogs should be donewhen
Leishmania is incidentally found in lesions that clearly
have a different origin. For example, several reports
describe the association between the presence of
amastigotes and neoplasms such as lymphoma, trans-
missible veneral tumors, and others.162–167 In such
cases, it is important to determine whether the dog is
affected by both diseases or affected by a neoplastic dis-
ease while simply being infected with Leishmania sp.
Histology
Histology can demonstrate the presence of Leishmania
in routinely hematoxylin- and eosin-stained sections
when cytology is negative on tissues with a cytologic
pattern highly consistent with leishmaniasis. Com-
pared with PCR and cytology, histology has 2 main dis-
advantages: it is more laborious and time-consuming,
and the identification of amastigotes may be more dif-
ficult than in cytologic samples. However, amastigotes
can be confirmed by immunohistochemistry (Fig-
ure 6)26,168, in situ hybridization169,170, or PCR on for-
malin-fixed and paraffin-embedded specimens.142,143
On the other hand, histology has the advantage of pro-
viding additional information on the cytoarchitectural
pattern of the lesions. This is a great advantage as it
may allow to discriminate between dogs in which the
parasite is associated with typical lesions and those in
which the infection does not seem to be associated
with the disease. Therefore, according to some guideli-
nes171, histology should always be performed. The
interpretation of histologic results is well documented
by numerous publications describing the typical
lesions and the distribution of parasites associated with
active disease, mostly characterized by lymphoplasma-
cytic or granulomatous-pyogranulomatous inflamma-
tion and/or by vasculitis either in organs usually
affected by Leishmania (bone marrow, spleen, skin,
lymph nodes, kidney, etc), and also in unusual tissues
such as heart, lung, adrenal gland, genital tract, cen-
tral nervous system, skeletal muscle, gastrointestinal
tract, nails, lacrimal glands, and ocular muscles.19–
21,23,26,50,55,56,58,60,61,98,160,172–181
Parasite culture and biologic test for
infectiousness (xenodiagnosis)
Conclusive diagnosis of active infection should be
based on tissue cultures, which not only confirm
Figure 6. Immunohistochemical detection of amastigotes in canine
leishmaniasis. There are positive brown staining amastigotes within the
cytoplasm of macrophages. Diaminobenzidine chromogen, hematoxylin
counterstain, bar = 20 lm. (Courtesy of Prof. Eugenio Scanziani,
MAPLab, Fondazione Filarete, Milan, and Dr. Raffaella Bergottini – Helab
–Milan).
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whether dogs harbor parasites but also demonstrate
that the protozoa are viable. A diagnostic Leishmania
sp. culture requires biphasic blood-agar media with
fresh components.126 A conclusive test for infectious-
ness (xenodiagnosis) requires that naive (laboratory-
reared) sand flies are allowed to feed on infected dogs
and are examined thereafter for the presence of pro-
mastigotes in the gut.182 However, both tests are
unpractical and restricted to specialized reference cen-
ters. Therefore, these tests are mainly intended for
research and cannot be recommended for routine
practice.
Future Perspectives
Several studies investigated the diagnostic potential of
innovative markers in leishmaniotic dogs. For exam-
ple, iron superoxide dismutase (Fe-SODe) secreted by
the parasite has been evaluated as a possible marker of
infection.183 Proteomic analysis has revealed a series of
proteins that are over- or underexpressed in leishman-
iotic dogs.184 The expression level of cytokines or
molecules such as leptin or inducible nitric oxide syn-
thetase in blood or tissues is different in leishmaniotic
dogs compared to controls11,13,185–187, and increased
activities of matrix metalloproteinases have been
reported in serum or CSF of leishmaniotic dogs.188,189
Recently, the scientific attention has been focused on
markers of oxidative stress. Inflammation is character-
ized by the release of reactive oxygen metabolites from
phagocytes recruited to inflammatory sites, eventually
leading to a consumption of antioxidant com-
pounds.190 Accordingly, increased concentrations of
oxidants or oxidized molecules (eg, reactive oxygen
metabolites, malonyldialdeide, lipoperoxides, thiobar-
bituric acid reactive substances) and decreased concen-
trations of antioxidant compounds (total antioxidant
capacity, trace elements, paraoxonase) have been
reported in leishmaniotic dogs.114,117,118,191–194
However, none of the studies cited above pro-
vided, to date, exhaustive information on the possible
practical diagnostic applicability of thesemarkers. Nev-
ertheless, preliminary results from these investigations
are encouraging and useful in design of future research
to explore their potential clinical application.
Tests for monitoring the posttreatment follow-up
Laboratory tests during the follow-up should be
focused on the monitoring of possible toxic effects of
treatment as well as the clinical and the parasitologic
status of the patient following administration of drugs
according to conventional treatments protocols. These
mainly include the administration of antimonials or
miltefosine, both in combination with allopurinol.
Alternative drugs should be carefully considered only
when conventional treatments are not effective.195
Monitoring the possible toxic effect of treatment
Theoretically, the possible toxic effects of treatment
should be monitored. However, despite some studies
which reported possible nephrotoxicity of antimoni-
als61,196, others did not confirm this finding.197 Recent
investigations demonstrated that no toxic effects on
cardiac or pancreatic tissue are induced by these drug
classes in dogs, differently from what is observed in
human patients.198,199 Therefore, toxic effects should
be monitored only in selected dogs, particularly when
peculiar clinical findings are present or history might
suggest any drug adversity.
The only possible adverse effect of allopurinol
is the formation of xanthine crystals in urine and
possibly urolithes.200 These crystals occur very fre-
quently201 and may sometimes be abundant. How-
ever, associated clinical signs and urolith formation
are not common and suspension of treatment is
unusual. Therefore, the analysis of urine sediment
should always be included in the laboratory data-
base when allopurinol is administered for a long
time or when urine appears macroscopically turbid
or forms an evident pellet after centrifugation
(Figure 7).
Figure 7. Urine sediment from a dog with leishmaniasis treated with
allopurinol. Xanthine crystals appear as roundish brown-yellow crystals
of different size, single or forming small to medium clusters. Unstained
sediment, bar = 15 lm. (Courtesy of Dr. Tiziana Vitiello, DiMeVet,
University of Milan).
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Monitoring the clinical status
As the clinical presentation of leishmaniasis in dogs
can be extremely variable, it is not possible to
define, a priori, a common and standardized labora-
tory procedure to be used during the follow-up.
However, 2 main aspects must always be moni-
tored, namely the presence of renal disease and
systemic inflammation.
Renal function should be evaluated through
the analysis of serum concentrations of creatinine
and, especially, through sequential quantification of
proteinuria, due to its role as a risk factor for the
progression of CKD.83 Proteinuria has been recently
shown to be a negative prognostic factor in leish-
maniotic dogs.105 After conventional leishmanicidal
treatment, the degree of proteinuria decreases in 4–
8 weeks202, thus, additional pharmacologic treat-
ments for proteinuria should be decided thereafter.
The possibility to restore normal renal function
depends on the severity of renal damage at the
time of first diagnosis. Therefore, serum creatinine
and proteinuria should be repeatedly assessed dur-
ing the follow-up. The frequency of testing depends
on the severity of CKD. Dogs in IRIS stages 3 or
464 should be frequently tested also during the
treatment period, while dogs in IRIS stages 1 or 264
should be tested at the end of the first treatment
cycle. Posttreatment evaluation should be done
after 12 months in stage 1 dogs, every 6 months in
dogs in stage 2, every 3 months in dogs in stage 3,
and every 6 weeks in dogs in stage 4.203,204
The inflammatory status may be monitored
through sequential analysis of electrophoretograms
and of APP. The simple evaluation of total pro-
teins, albumin, or albumin-to-globulin (A/G) ratio,
may not be helpful because it is very likely that,
despite decreases in globulin concentrations in
response to treatment, albumin concentrations will
remain low in dogs with persistent glomerular
damage and proteinuria, in turn leading to only
minor changes in the A/G ratio. Serum protein
electrophoresis can be used to monitor a progres-
sive decrease of a-and c-globulins with successful
treatment. These changes start to become evident
after 2–3 weeks and 4–6 weeks, respectively, fol-
lowing treatment with antimonials.205 Therefore,
the first useful electrophoretogram to monitor the
efficiency of treatment should be run no earlier
than one month after treatment initiation.203 The
complete normalization of electrophoretograms,
however, requires at least 90–120 days.200 If after
2–3 months the electrophoretograms still show
abnormal profiles, the possible presence of concur-
rent diseases such as other vector-borne infections
should be considered, especially if the gammopathy
tends to be characterized by narrower peaks (Fig-
ure 3). Treatments with miltefosine or with other
drugs may require more time to be beneficial
(more than 2 months to observe a decrease in c-
globulins) and are also characterized by more
frequent relapses after transient normalization of
laboratory profiles.206,207
Compared with serum protein electrophoresis,
monitoring the concentration of APPs provides earlier
information regarding the success of treatments with
antimonials. C-reactive protein and SAA start to
decrease within 2 weeks after treatment and may
return to within the RI in about one month.115,116,205
The normalization of PON-1 and HDL is even more
rapid: significant increases may be observed 3–7 days
after treatment and values return to within the RIs in
2 weeks.75,205 Therefore, to assess the efficacy of treat-
ment, it may be advisable to measure the serum activ-
ity of PON-1 or the concentration of HDLs or APPs one
to 2 weeks after the first administration of drugs, when
other clinical or clinicopathologic changes are likely
still abnormal.
Monitoring the parasitologic status
As at first diagnosis, the parasitologic status can be
monitored indirectly, through the assessment of anti-
body titers, or by direct evaluation of parasite presence.
In case of successful treatment, a decrease in antibody
titers may be expected over time; hence, serology
should be repeated during the follow-up.203 Significant
reduction in titers can be detected by 30 days post
treatment in sick or severely sick dogs with good clini-
cal response to therapy.208,209 However, most of the
responders will show a noticeable decrease of titers
about 6 months after initiation of treatment.200 It
should be kept in mind that a complete disappearance
of antileishmanial antibodies is unlikely, especially in
dogs living in endemic areas that may be repeatedly
exposed to the parasite, boosting the antibody response.
Therefore, sequential serologic testing during the fol-
low-up is intended to see a decreasing antibody titer
reaching values consistent with simple exposure (ie,
< 4-fold the threshold value of the laboratory).14
In order to assess whether treatment leads to com-
plete elimination of the infection, ideally the presence
of parasites should be assessed in tissues where Leish-
mania sp. typically establishes a latent infection and
using very sensitive techniques such as repeated quan-
titative PCR analyses on bone marrow, spleen, or
lymph nodes.14 However, this procedure is invasive
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and owner compliance may be challenging in cases
where treatment appears successful and the dog looks
clinically healthy. Therefore, in routine practice, the
evaluation of treatment efficacy is usually assessed by
serology or quantitative PCR analysis of blood. If treat-
ment has been successful, quantitative PCR should
show a clear reduction in Leishmania DNA copies after
3–6 months of therapy, with complete absence
between 6 and 12 months.138
Concluding Remarks and Recommended
Protocols
Diagnosing leishmaniasis in dogs may be difficult due
to the complex pathogenesis and broad spectrum of
clinical and clinicopathologic findings. Hence, tests
that need to be included in the diagnostic protocol may
vary according to case presentation or epidemiologic
scenario (Figure 8).210
Figure 8. Flowchart illustrating the recommended diagnostic approach and laboratory tests for clinically healthy dogs living in or traveling to endemic
regions, or for dogs showing clinical signs consistent with leishmaniasis.
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In dogs with a strong clinical suspicion of leishma-
niasis, the use of quantitative serology is advisable, as it
can be conclusive for diagnosis when high titers of
antibodies are present. In clinically healthy dogs living
in or having traveled to an endemic area, again serol-
ogy may be the test of choice to assess any possible
exposure to parasites. Based on the median time
required for seroconversion133, serology should be per-
formed at least 6 months after exposure (eg, in Febru-
ary–March where transmission is seasonal, or every 6–
12 months where transmission occurs all year long). If
serology is positive, it is important to determine the
antibody titer. A low antibody titer may be consistent
with exposure or an early phase of infection, while a
high antibody titer can be suggestive of infection or dis-
ease.14,15 Therefore, the subsequent diagnostic steps
should confirm the suspected infection by cytologic
and PCR analysis of target tissues, and/or by identifica-
tion of typical clinical or laboratory alterations, espe-
cially in dogs with high antibody titers. If serology or
PCR are positive and samplings have been performed
during a nontransmission period, the laboratory
workup should aim to identify the most common
abnormalities in dogs with leishmaniasis in the
absence of overt clinical signs (eg, anemia, abnormal
serum protein electrophoresis, proteinuria). In the
presence of typical changes, additional clinical or labo-
ratory tests must be performed in order to stage the dis-
ease (eg, tests recommended by the IRIS guidelines for
CKD64 and/or APP for inflammation).
If a dog is examined because of clinical abnormali-
ties, the veterinarian should sample any accessible
lesion to obtain cytologic smears or biopsies.15 If Leish-
mania sp. amastigotes are documented and the cyto-
logic or histologic pattern is consistent with
leishmaniasis, the dog should be considered sick. Thus,
next diagnostic steps should clarify whether there is a
systemic involvement (eg, hematologic disorders,
inflammation, nephropathy) and the antileishmanial
antibodies and/or the parasite burden should be quan-
tified with quantitative PCR to obtain baseline values
useful for monitoring. Conversely, if amastigotes are
not observed but cytologic patterns are consistent with
leishmaniasis, the lesion can be further analyzed by
histology combined with immunohistochemistry,
in situ hybridization, or PCR.14,15 A positive result with
one of these additional tests should lead to further
investigation of the general health status of the sick
dog. Conversely, if these tests are negative, the pres-
ence of infection should be assessed in the bone mar-
row through cytology and/or PCR and, in case of
positive results, further clinicopathologic tests should
be performed as discussed above.14,15
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